Skip to main content
. Author manuscript; available in PMC: 2020 Sep 24.
Published in final edited form as: Lancet Oncol. 2015 Jul 13;16(8):937–948. doi: 10.1016/S1470-2045(15)00138-2

Table 2:

Summary of genotyping analyses done in the CORRECT trial

DNA source for genotyping Genotyping technology used Biomarker sampling frequency (n=760) Mutation frequency
KRAS Plasma* BEAMing 503 (66%) 349/503 (69%)
Archival tumour tissue BEAMing 239 (31%) 140/239 (59%)
Archival tumour tissue Historical† 729 (96%) 430/729 (59%)
PIK3CA Plasma* BEAMing 503 (66%)  84/503 (17%)
Archival tumour tissue BEAMing 236 (31%)  29/236 (12%)
BRAF Plasma* BEAMing 502 (66%)  17/502 (3%)
Archival tumour tissue BEAMing 269 (35%)  4/269 (1%)

Data are n (%) or n/N (%). Biomarker sampling frequency is the proportion of patients in CORRECT for whom mutation data were generated; for some patients, DNA samples were of insufficient quality or quantity to examine all three genes. Mutation frequency is the proportion of patients in CORRECT with mutation data who were identified as having a mutation in the specified gene.

*

Plasma samples were collected at the time of enrolment in CORRECT and before treatment with study drug.

†

Historical KRAS mutation data were generated before the start of the CORRECT trial using unknown testing technology and were reported to the study sponsor at the time of enrolment.